Volrustomig Priming Regimens Exploratory Phase II Platform Study - eVOLVE-01

Study identifier:D798KC00001

ClinicalTrials.gov identifier:NCT06448754

EudraCT identifier:N/A

CTIS identifier:2023-509482-20

Recruiting

Official Title

A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with Solid Tumors (eVOLVE-01)

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Volrustomig, Carboplatin, Pemetrexed

Sex

All

Estimated Enrollment

120

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 27 Aug 2024
Estimated Primary Completion Date: 06 Nov 2025
Estimated Study Completion Date: 08 Dec 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria